GuangYuYuan Chinese Herbal Medicine (SHSE:600771) Investors Are up 5.0% in the Past Week, but Earnings Have Declined Over the Last Five Years
GuangYuYuan Chinese Herbal Medicine (SHSE:600771) Investors Are up 5.0% in the Past Week, but Earnings Have Declined Over the Last Five Years
When we invest, we're generally looking for stocks that outperform the market average. And while active stock picking involves risks (and requires diversification) it can also provide excess returns. For example, long term GuangYuYuan Chinese Herbal Medicine Co., Ltd. (SHSE:600771) shareholders have enjoyed a 45% share price rise over the last half decade, well in excess of the market return of around 26% (not including dividends).
当我们投资时,通常寻找的是表现优于市场平均水平的股票。虽然积极的股票挑选涉及风险(并需要分散投资),但也可以提供额外回报。例如,长期持有广誉远中药股份有限公司(SHSE:600771)的股东在过去的半个十年中享受了股价上涨45%,远远超过了大约26%的市场回报(不包括股息)。
After a strong gain in the past week, it's worth seeing if longer term returns have been driven by improving fundamentals.
在过去的一周之内,获得的强劲收益是否表明了长期回报受到基本面的推动值得关注。
We don't think that GuangYuYuan Chinese Herbal Medicine's modest trailing twelve month profit has the market's full attention at the moment. We think revenue is probably a better guide. Generally speaking, we'd consider a stock like this alongside loss-making companies, simply because the quantum of the profit is so low. For shareholders to have confidence a company will grow profits significantly, it must grow revenue.
我们认为广誉远中药的近12个月的利润并未完全引起市场的注意。我们认为营业收入可能是更好的指南。一般来说,我们会将这样的股票与亏损公司一起考虑,仅仅是因为利润的数量非常低。对于股东来说,要相信公司会大幅增长利润,就必须增长营业收入。
In the last 5 years GuangYuYuan Chinese Herbal Medicine saw its revenue grow at 1.6% per year. That's not a very high growth rate considering the bottom line. The modest growth is probably broadly reflected in the share price, which is up 8%, per year over 5 years. We'd be looking for the underlying business to grow revenue a bit faster.
在过去的5年里,广誉远中药的营业收入以每年1.6%的速度增长。考虑到底线,这并不是一个非常高的增长率。这种适度的增长可能在股价中得到了广泛体现,这导致了过去5年中每年上涨8%的股价。我们期望基础业务能够更快地增长营业收入。
The company's revenue and earnings (over time) are depicted in the image below (click to see the exact numbers).
以下图像显示了公司的营业收入和盈利(随时间变化)(单击以查看准确的数字)。
Take a more thorough look at GuangYuYuan Chinese Herbal Medicine's financial health with this free report on its balance sheet.
通过这份免费的资产负债表报告,更全面地了解广誉远中药的财务状况。
A Different Perspective
另一种看法
While the broader market gained around 13% in the last year, GuangYuYuan Chinese Herbal Medicine shareholders lost 29%. However, keep in mind that even the best stocks will sometimes underperform the market over a twelve month period. On the bright side, long term shareholders have made money, with a gain of 8% per year over half a decade. If the fundamental data continues to indicate long term sustainable growth, the current sell-off could be an opportunity worth considering. While it is well worth considering the different impacts that market conditions can have on the share price, there are other factors that are even more important. For example, we've discovered 1 warning sign for GuangYuYuan Chinese Herbal Medicine that you should be aware of before investing here.
尽管更广泛的市场在过去一年中上涨了约13%,但广誉远中药的股东却损失了29%。然而,请记住,即使是最好的股票有时也会在十二个月的时间内表现不佳。从积极的一面看,长期股东已经赚到钱,过去五年中每年获利8%。如果基本数据继续表明长期可持续的增长,当前的抛售可能是值得考虑的机会。尽管考虑市场状况对股价的影响是非常重要的,但有其他更重要的因素。例如,我们发现了广誉远中药的一项警告信号,你在投资之前应该注意。
If you like to buy stocks alongside management, then you might just love this free list of companies. (Hint: many of them are unnoticed AND have attractive valuation).
如果您喜欢与管理层一起购买股票,那么您可能会喜欢这个公司的免费列表。 (提示:其中许多公司不为人注意且具有吸引力的估值。)
Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on Chinese exchanges.
请注意,本文中引用的市场回报反映了目前在中国交易所上市的股票的市场加权平均回报。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
对这篇文章有反馈吗?对内容感到担忧吗?请直接与我们联系。或者,发送电子邮件至editorial-team @ simplywallst.com。
Simply Wall St的这篇文章是一般性质的。我们仅基于历史数据和分析师预测提供评论,使用公正的方法,我们的文章并非意在提供财务建议。这并不构成买入或卖出任何股票的建议,并且不考虑您的目标或财务状况。我们旨在为您带来基于基础数据驱动的长期聚焦分析。请注意,我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St对提及的任何股票都没有持仓。